Luxembourg

Reimbursed Care Access

Luxembourg follows EU-wide regulatory approvals for novel psychiatric medicines: esketamine (Spravato) is EMA-authorised and can be prescribed under restricted conditions; racemic ketamine is an authorised anaesthetic and is used clinically (including off‑label in some settings) but not as an EMA‑approved antidepressant. Classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are listed under Luxembourg's narcotics legislation and have no routine medical reimbursement or authorised clinical use outside approved research. Clinical access for non‑authorised psychedelics is limited to approved clinical trials and exceptional research authorisations where applicable.